Good morning, everyone, and how are you today? A scorcher is predicted to envelope the Pharmalot corporate campus. We plan to keep cool by perusing interesting documents and chatting up interesting people. We will also break later to appear on a PhRMA panel on social media. To prepare, we are downing a few cups of stimulation - our flavor today is Southern Pecan. Meanwhile, here are some nifty tidbits from around your world. Watch out for the heat and see you soon...
Pfizer Teams With Harvard In $100M Drug Discovery Deal (Bloomberg News)
Merck Ends Trial Of Intercell Vaccine For MRSA (Reuters)
Covidien Seeks A Buyer For Its Pharma Unit (Bloomberg News)
Orphan Drug Development Success Remains Elusive (Gen New)
US Seeks Prison Sentences For Device Execs (Associated Press)
Glaxo Faces Advair Threat After Sweden OKs Generic (Pharma Times)
Body Imaging Business Pushes Scans That Few Need (ProPublica)
Cancer Drug Shortage Has Doctors Scrambling (Reuters)
Will UN AIDS Meeting Limit Generic Distribution? (IPS)
Medco Under Pressure As Big Contract Renewal Looms (Bloomberg News)
Parexel To Close Four Sites As Part Of Restructuring (Outsourcing Pharma)
Prices Stop 10 Percent Of Australians From Getting Meds (Pharma Times)
US Market For Functional Excipients To Hit $2B By 2015 (InPharma Technologist)
Biogen Seeks Deals To Expand MS Pipeline (Bloomberg News)
water bottle thx to muffet on flickr
1 Comment
Parexel's move is simply obeying Sutton's Law.